Depression and Dopamine Transporter Function Study Using C-11 Altropane

Mass General Brigham

Status: Completed

Conditions: Major Depressive Disorder; Anhedonia

Study type: Observational

Funder types: Other

Identifiers

NCT01701141

2009-P-001360

Details and patient eligibility

About

Major depressive disorder (MDD) is often characterized by anhedonia and impaired ability to modulate behavior as a function of rewards. However, the neurobiology of anhedonia and reduced reward responsiveness remains largely unknown. Because dopamine (DA) plays a critical role in goal-directed behavior and reinforcement learning, DA dysregulation might play an important role. In fact, several lines of evidence suggest that down-regulation of DA transmission might characterize depression vulnerability and the emergence of depressive symptoms. The current study seeks to elucidate the role of DA dysfunction in MDD. We hypothesize that MDD subjects will show reduced DAT binding potential, reduced reward learning in the probabilistic reward task, and abnormal functional magnetic resonance imaging (fMRI) activation in dorsal and ventral striatal regions during an instrumental learning task.

This study will include three sessions.

The first will take place at Massachusetts General Hospital or at McLean Hospital's Center for Depression, Anxiety and Stress Research. The aims of this session will be to (a) explain the study; (b) collect written informed consent, and (c) assess the subject's eligibility.

Following this, another session (either second or third in order) will take place at the MGH PET Imaging Laboratory. Participants will complete a PET scan and a probabilistic reward task designed to measure reward learning and sensitivity to reward. The radioactive tracer utilized is 11C-altropane.

Another session (either second or third in order) will take place at the McLean Hospital Neuroimaging Center. Participants will complete an instrumental learning task while in the fMRI, followed by a social reinforcement learning task and an implicit learning serial reaction time task upon completion of the scan. In the instrumental learning task, participants have the opportunity to earn money but need to learn, by trial and error, stimulus-outcome associations. The social reinforcement learning task is designed to investigate whether learning deficits in MDD are specific to learning from monetary incentives or whether the learning deficits are more global and are affected when learning from social rewards and punishments. Participants will also complete an implicit learning serial reaction time task, designed to exclude the possibility of global learning deficits in MDD.

Enrollment: 150 estimated patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Criteria for All Subjects

Inclusion Criteria:

1. Written informed consent;
2. Both genders and all ethnic origins, age between 18 and 45;
3. Right-handed (Chapman and Chapman 1987);
4. Absence of any medications for at least 3 weeks;
5. Absence of pregnancy;
6. Absence of current drug use (cocaine, cannabinoids, opiates, amphetamines, benzodiazepines and barbiturates) as assessed by urinary drug test.
7. For women, completion of a negative urine pregnancy test prior to the MRI scan, as well as a negative STAT quantitative serum hCG test immediately prior to radiopharmaceutical exposure;
8. Normal or corrected-to-normal vision and hearing.

Exclusion Criteria

1. Pregnant or currently breast-feeding women or any woman of childbearing potential who is seeking to become pregnant or suspects that she may be pregnant.
2. History or current serious or unstable medical illness, including cancer, cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease;
3. History of seizure disorder;
4. Failure to meet standard PET safety requirements;
5. Failure to meet standard fMRI safety requirements;
6. Students and employees supervised by the Investigators at MGH, McLean Hospital and Harvard University;
7. Absence of fluency in written and spoken English;
8. History of head injury;
9. History or current use of cocaine, stimulants, or other dopaminergic drugs.
10. Diabetes with poor glucose control;
11. History or current diagnosis of dementia, or a score of < 26 on the Mini Mental Status Examination (Folstein, 1975) at the screening visit;
12. Clinical or laboratory evidence of hypothyroidism or currently taking thyroid medication;
13. Currently taking medication that affects blood flow, e.g. certain blood pressure medications
14. Evidence of significant inconsistencies in self-report.

Criteria Specific to MDD subjects

Inclusion Criteria:

1. DSM-IV diagnostic criteria for MDD (diagnosed with the use of the SCID);
2. A baseline HRSD score (Hamilton 1960) greater than or equal to 16 (17-item version);

Exclusion Criteria:

1. Subjects with suicidal ideation where outpatient treatment is determined unsafe by the study clinician. These patients will be immediately referred to appropriate clinical treatment;

2. History or current diagnosis of: learning and developmental disorders (including ADHD and autism spectrum disorders), anorexia nervosa, cognitive disorders, somatoform and factitious disorders, dissociative disorders, personality disorders, organic mental disorders, schizophrenia or other psychotic disorder, bipolar disorder, obsessive compulsive disorder; simple phobia, social anxiety disorder and generalized anxiety disorder are allowed if secondary to MDD.

3. History of substance dependence lifetime or substance abuse within the last 12 months;

4. History of bulimia nervosa or PTSD within the past 2 years;

5. History or current diagnosis of dementia, or a score of < 26 on the Mini Mental Status Examination (Folstein, 1975) at the screening visit;

6. Current use of other psychotropic drugs;

7. Patients with lifetime electroconvulsive therapy (ECT);

8. Presence of any psychotropic medications for at least 2 weeks:

   • 6 months for dopaminergic drugs (including methylphenidate),
   • 6 weeks for fluoxetine,
   • 6 months for neuroleptics,
   • 2 weeks for benzodiazepines,
   • 2 weeks for any other antidepressants.

Criteria Specific to Control subjects

Inclusion Criteria:

1. Absence of medical, neurological, and psychiatric illness (including alcohol and substance abuse), as assessed by subject history and a structured clinical interview (SCID-I/NP);
2. Absence of any medications for at least 3 weeks;

Exclusion Criteria:

1. History or current diagnosis of any of DSM-IV psychiatric illness;
2. First degree relative with mood disorder or psychosis;
3. History or current use of any psychiatric medication.

Trial design

150 participants in 2 patient groups

Individuals with MDD

Description:

Individuals with current MDD as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment.

Healthy Controls

Description:

Individuals with no psychiatric diagnosis as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment